PTC Stock Recent News

Industry's first MBD offering delivering complete digital definition of a product within a cloud-native CAD and PDM solution Cloud-native MBD in Onshape enables better collaboration between engineering, supply chain, and manufacturing teams PTC and Aura Aero, a leader in sustainable aviation, will preview cloud-native MBD in Onshape at Paris Air Show BOSTON , June 12, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced model-based definition (MBD) capabilities within its Onshape® computer-aided design (CAD) and product data management (PDM) platform. MBD in Onshape is the first MBD offering within a cloud-native CAD and PDM solution and enables engineering teams to create a complete digital definition of a product by embedding all common product manufacturing information (PMI) directly into the 3D CAD model, including dimensions, tolerances, annotations, surface finishes, material specifications, and more.

PTC recently delivered good quarterly results, beating revenue and earnings estimates, but customer caution may slow growth in the second half of fiscal 2025. Recent sales team restructuring and a focus on vertical markets are promising, yet macroeconomic pressures are causing management to guide conservatively. PTC's capital allocation has been efficient enough, with significant stock buybacks offsetting high stock-based compensation, but ARR growth guidance has been trimmed to 9%.

NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Nvidia's (NVDA 0.51%) recent earnings report boosted the market and alleviated concerns about any slowdown in artificial intelligence (AI) and data-center-related spending. That's great news for Nvidia and other frontline players in the AI/data center industry.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.